celecoxib has been researched along with Peritoneal Neoplasms in 10 studies
Peritoneal Neoplasms: Tumors or cancer of the PERITONEUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Celecoxib was to be continued after DC termination up to 3 years." | 6.77 | A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the Do ( de Graaf, H; de Munck, L; Erdkamp, FLG; Hoekman, K; Hollema, H; Lalisang, RI; Polee, M; Reyners, AKL; Schaapveld, M; Smit, WM; van Vugt, MATM; Willemse, PHB; Wymenga, ANM, 2012) |
| "Celecoxib is a potent selective COX-2 inhibitor." | 5.32 | [A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP]. ( Hada, M; Kazuhiro, M, 2004) |
| "Celecoxib was to be continued after DC termination up to 3 years." | 2.77 | A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the Do ( de Graaf, H; de Munck, L; Erdkamp, FLG; Hoekman, K; Hollema, H; Lalisang, RI; Polee, M; Reyners, AKL; Schaapveld, M; Smit, WM; van Vugt, MATM; Willemse, PHB; Wymenga, ANM, 2012) |
| "Pancreatic cancer is amongst the most chemoresistant malignancies." | 2.71 | A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. ( Adsay, V; El-Rayes, BF; Ferris, AM; Heilbrun, LK; Philip, PA; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM, 2005) |
| "Mesenteric fibromatosis is currently a diagnostic and therapeutic challenge." | 1.34 | Resolution of hydronephrosis due to massive mesenteric fibromatosis using cyclo-oxygenase 2 inhibitors. ( Chang, CH; Chen, YF; Ng, TY; Yang, MD, 2007) |
| "Celecoxib is a potent selective COX-2 inhibitor." | 1.33 | [A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine]. ( Hada, M; Horiuchi, T; Shinji, H, 2006) |
| "Celecoxib is a potent selective COX-2 inhibitor." | 1.32 | [A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP]. ( Hada, M; Kazuhiro, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vierra, M | 1 |
| Dhiman, A | 1 |
| Witmer, HDD | 1 |
| Ulrich, L | 1 |
| Hindi, E | 1 |
| Fenton, E | 1 |
| Shergill, A | 1 |
| Polite, B | 1 |
| Eng, OS | 1 |
| Turaga, KK | 1 |
| Ramanathan, R | 1 |
| Choudry, H | 1 |
| Jones, H | 1 |
| Girgis, M | 1 |
| Gooding, W | 1 |
| Kalinski, P | 1 |
| Bartlett, DL | 2 |
| Gupta, R | 1 |
| Cristea, M | 1 |
| Frankel, P | 1 |
| Ruel, C | 1 |
| Chen, C | 1 |
| Wang, Y | 1 |
| Morgan, R | 1 |
| Leong, L | 1 |
| Chow, W | 1 |
| Koczywas, M | 1 |
| Koehler, S | 1 |
| Lim, D | 1 |
| Luu, T | 1 |
| Martel, C | 1 |
| McNamara, M | 1 |
| Somlo, G | 1 |
| Twardowski, P | 1 |
| Yen, Y | 1 |
| Idorenyi, A | 1 |
| Raechelle, T | 1 |
| Carroll, M | 1 |
| Chung, V | 1 |
| Shatzel, J | 1 |
| Wooten, K | 1 |
| Ankola, A | 1 |
| Cheney, RT | 1 |
| Morrison, CD | 1 |
| Skitzki, JJ | 1 |
| Choudry, HA | 1 |
| Mavanur, A | 1 |
| O'Malley, ME | 1 |
| Zeh, HJ | 1 |
| Guo, Z | 1 |
| Reyners, AKL | 1 |
| de Munck, L | 1 |
| Erdkamp, FLG | 1 |
| Smit, WM | 1 |
| Hoekman, K | 1 |
| Lalisang, RI | 1 |
| de Graaf, H | 1 |
| Wymenga, ANM | 1 |
| Polee, M | 1 |
| Hollema, H | 1 |
| van Vugt, MATM | 1 |
| Schaapveld, M | 1 |
| Willemse, PHB | 1 |
| Hada, M | 2 |
| Kazuhiro, M | 1 |
| El-Rayes, BF | 1 |
| Zalupski, MM | 1 |
| Shields, AF | 1 |
| Ferris, AM | 1 |
| Vaishampayan, U | 1 |
| Heilbrun, LK | 1 |
| Venkatramanamoorthy, R | 1 |
| Adsay, V | 1 |
| Philip, PA | 1 |
| Horiuchi, T | 1 |
| Shinji, H | 1 |
| Ng, TY | 1 |
| Yang, MD | 1 |
| Chen, YF | 1 |
| Chang, CH | 1 |
4 trials available for celecoxib and Peritoneal Neoplasms
| Article | Year |
|---|---|
Phase II Trial of Adjuvant Dendritic Cell Vaccine in Combination with Celecoxib, Interferon-α, and Rintatolimod in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Cytoreduction Surgi | 2021 |
Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents | 2019 |
A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the Do
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2012 |
A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2005 |
6 other studies available for celecoxib and Peritoneal Neoplasms
| Article | Year |
|---|---|
Celecoxib and Myrtol: A Novel Therapy for Recurrent Appendiceal Mucinous Neoplasms With Extensive Peritoneal Dissemination.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; C | 2022 |
Inflammatory myofibroblastic tumor of the mesentery: a clinical dilemma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Inflammatory Agents; Celecoxib; Female; Humans; | 2012 |
Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Appendiceal Neoplasms; Celecoxib; Colonic N | 2012 |
[A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cisplatin; Combined Modality Therapy; Dru | 2004 |
[A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug Administration | 2006 |
Resolution of hydronephrosis due to massive mesenteric fibromatosis using cyclo-oxygenase 2 inhibitors.
Topics: Adult; Celecoxib; Cyclooxygenase 2 Inhibitors; Fibroma; Gardner Syndrome; Humans; Hydronephrosis; La | 2007 |